RESUMEN
The potential of microporous zeolites FAU and BEA, and mesoporous MCM-41, for prolonged release of atenolol in drug delivery systems was investigated both experimentally, using drug release studies, and theoretically using classical molecular dynamics simulations. Remarkably, zero-order release of atenolol was achieved from FAU (SiO2:Al2O3 = 80:1) into phosphate buffer for 24 h followed by prolonged release for at least another 48 h. Experimental data also demonstrate the ability for all of the drug-zeolite combinations investigated to achieve prolonged release of atenolol, with the release rates determined by the combination of framework topology, aluminium content and drug release study media. Molecular dynamics simulations give an insight into the reasons for the different release rates observed for FAU and BEA. The results of this work emphasise the need for sophisticated models in order to explain subtle differences in release, such as those observed at different SiO2:Al2O3 ratios.
Asunto(s)
Zeolitas , Atenolol , Sistemas de Liberación de Medicamentos , Dióxido de SilicioRESUMEN
Tuberculosis and nutrition are intrinsically linked in a complex relationship. Altered metabolism and loss of appetite associated with tuberculosis may result in undernutrition, which in turn may worsen the disease or delay recovery. We highlight an updated Cochrane review assessing the effects of oral nutritional supplements in people with active tuberculosis who are receiving antituberculosis drug therapy. The review authors conducted a comprehensive search (February 2016) for all randomised controlled trials comparing any oral nutritional supplement, given for at least 4 weeks, with no nutritional intervention, placebo or dietary advice only in people receiving antituberculosis treatment. Of the 35 trials (N=8 283 participants) included, seven assessed the provision of free food or high-energy supplements, six assessed multi-micronutrient supplementation, and 21 assessed single- or dual-micronutrient supplementation. There is currently insufficient evidence to indicate whether routinely providing free food or high-energy supplements improves antituberculosis treatment outcomes (i.e. reduced death and increased cure rates at 6 and 12 months), but it probably improves weight gain in some settings. Plasma levels of zinc, vitamin D, vitamin E and selenium probably improve with supplementation, but currently no reliable evidence demonstrates that routine supplementation with multi-, single or dual micronutrients above the recommended daily intake has clinical benefits (i.e. reduced death, increased cure rate at 6 and 12 months, improved nutritional status) in patients receiving antituberculosis treatment. In South Africa, most provinces implement a supplementation protocol based on nutritional assessment and classification of individuals rather than on disease diagnosis or treatment status.
Asunto(s)
Antituberculosos/uso terapéutico , Suplementos Dietéticos , Desnutrición , Micronutrientes/uso terapéutico , Tuberculosis , Adulto , Niño , Femenino , Humanos , Masculino , Desnutrición/diagnóstico , Desnutrición/etiología , Desnutrición/metabolismo , Desnutrición/prevención & control , Evaluación Nutricional , Estado Nutricional/efectos de los fármacos , Gravedad del Paciente , Literatura de Revisión como Asunto , Sudáfrica/epidemiología , Resultado del Tratamiento , Tuberculosis/complicaciones , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Tuberculosis/metabolismo , Aumento de Peso/efectos de los fármacosRESUMEN
The preparation of nanomedicines can be achived using a host of methods ranging from wet-chemical approaches to more engineering related techniques. As a maturing branch of nanotechnology, nanomedcines are being tailored to serve multiple pharmaceutic and biomedical related funcitons (e.g. targeted delivery, imaging, healing, sensing which may require the utilisaiton of one or more actives or excipients. In some instances, handling of materials (such as sensitive biomolecules or active pharmaceutical ingredient) becomes a limiting factor along with issues related to fabrication steps (loss or degradation of active components and functional materials, deposition location & procedure (removal of formed structures, process environment sensitivity and scale-up potential. This short review focuses on the electrohydrodynamic preparation of emerging nanomedicines that have potential to serve as therapeutic platforms. An insight into the underpinning process (jet-formation, related paramerts (material and process and strucutral outcomes (particles and fibres is given in relation to highlighted research. The ambient temperature processing, user friendly preparation and present industrial scale up potential (now in kg/hr make such processes valuable in the preparation of future nano-scaled and sensitive dosage forms.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Técnicas Electroquímicas/métodos , Nanomedicina/métodos , Nanotecnología/métodos , Técnicas Electroquímicas/instrumentación , Diseño de Equipo , Excipientes/química , Técnicas de Transferencia de Gen , Humanos , Nanofibras/química , Nanopartículas/química , Nanotecnología/instrumentación , Neoplasias/tratamiento farmacológicoRESUMEN
In this study, minitablet and granule formulations were developed as solid oral dosage forms for the delivery of peptide drugs with the absorption enhancer N-trimethyl chitosan chloride (TMC). Minitablets were deemed suitable as a dosage form due to their ability, as components of multiple unit dosage forms (MUDFs), to disperse from each other, before disintegration, effectively increasing the area in which the polymer can assert its absorption-enhancing effect. The polymer should be released from the dosage forms prior to the release of the peptide, which was, together with achieving maximum release of both ingredients, the main focus of this study. Desmopressin (1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (DDAVP) was used as model peptide drug. The optimized minitablet formulation consisted of two types of granules, namely DDAVP and TMC granules. DDAVP granules, containing tetraglycerol pentastearate (TGPS), were specifically aimed at delaying the release of the peptide from the dosage form. Burst release of TMC was attempted with TMC granules. Both these granule types were included in the granule formulation. Release profiles for both the optimized minitablet formulation as well as the granule formulation showed that the release of DDAVP was effectively delayed from the formulation compared to the formulation where no attempt at delaying the release was made. In comparison, more TMC was released, and at a faster rate, from the granule formulation than the optimized minitablet formulations. Both the optimized minitablet formulation and the granule formulation show suitable release profiles for the delivery of peptide drugs with TMC as absorption enhancer in solid oral dosage forms.
Asunto(s)
Administración Oral , Quitosano/farmacocinética , Sistemas de Liberación de Medicamentos/métodos , Absorción Intestinal/efectos de los fármacos , Péptidos/farmacocinética , Adhesivos/química , Transporte Biológico/efectos de los fármacos , Cápsulas/química , Cápsulas/farmacocinética , Quitosano/síntesis química , Desamino Arginina Vasopresina/análisis , Desamino Arginina Vasopresina/química , Desamino Arginina Vasopresina/farmacocinética , Evaluación Preclínica de Medicamentos , Excipientes/química , Excipientes/farmacocinética , Humanos , Absorción Intestinal/fisiología , Moco/química , Pectinas/química , Pectinas/farmacocinética , Péptidos/química , Solubilidad/efectos de los fármacos , Comprimidos/química , Comprimidos/farmacocinética , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/tendencias , Factores de TiempoRESUMEN
The absorption enhancing effects of chitosan and its derivatives have been intensively studied in recent years. It has been shown that these compounds are potent absorption enhancers. Chitosan is only soluble in acidic environments and is therefore incapable of enhancing absorption in the small intestine, the main absorption area in the gastrointestinal tract. Special emphasis has been placed on the absorption enhancing properties of N-trimethyl chitosan chloride (TMC), a partially quaternised derivative of chitosan, due to its solubility in neutral and basic environments. TMC is prepared by the reductive methylation of chitosan. The degree of quaternisation can be altered by increasing the number of reaction steps or by increasing the reaction time. Although the molecular weight of the polymer increases with addition of the methyl groups, a net decrease in the molecular weight is observed due to a decrease in the chain length of the polymer. TMC, like chitosan, possesses mucoadhesive properties. In vitro studies performed on Caco-2 cell monolayers showed a pronounced reduction in the transepithelial electrical resistance (TEER). TMC is also able to increase the permeation of hydrophilic compounds such as [14C]-mannitol and [14C] polyethylene glycol 4000 ([14C] PEG 4000, MW4000) across the cell monolayers. It was also shown that the degree of quaternisation of the polymer plays an important role on its absorption enhancing properties, especially in neutral environments where chitosan is ineffective as an absorption enhancer. The reduction in TEER is an indication of the opening of the tight junctions located between epithelial cells. Opening of the tight junctions will result in enhancement of absorption via the paracellular route. Confocal laser scanning microscopy confirmed transport of large hydrophilic compounds via the paracellular route as well as the mechanism of action of the polymer in which redistribution of the cytoskeletal F-actin is provoked, which leads to the opening of the tight junctions. Various in vivo studies in different animal models confirmed the ability of TMC to increase the absorption of the peptide drugs buserelin and octreotide after intraduodenal or -jejunal administration. However, TMC has always been administered as a solution in these studies. The impracticality of administering a solution, as well as the fact that most peptides are unstable in the presence of water, have led to the need for a solid oral dosage form with which TMC can be administered together with peptide drugs. Recent studies have focused on the development and in vivo evaluation of solid oral dosage forms.
Asunto(s)
Adyuvantes Farmacéuticos/química , Quitosano/química , Portadores de Fármacos/química , Péptidos/administración & dosificación , Adyuvantes Farmacéuticos/farmacología , Administración Oral , Animales , Química Farmacéutica , Quitosano/farmacología , Humanos , Péptidos/química , Péptidos/farmacocinética , Factores de TiempoRESUMEN
Two hundred and seventy-five serum samples from cattle in Malawi were tested as a pilot survey for Leptospira antibody titres. Fifty-nine (21.4%) of the animals were positive for leptospirosis, while 35 (12.7%) animals reacted inconclusively. Titres to L. hardjo and L. pomona serovars were the most prevalent. Results are also discussed with reference to the areas where samples were collected.
Asunto(s)
Anticuerpos Antibacterianos/análisis , Enfermedades de los Bovinos/inmunología , Leptospirosis/veterinaria , Animales , Bovinos , Enfermedades de los Bovinos/epidemiología , Leptospirosis/epidemiología , Leptospirosis/inmunología , Malaui/epidemiologíaRESUMEN
Fifty sera collected from 12 different species of free-living game animals in game parks in the Northern Natal were tested against 8 Leptospira interrogans antigens using the microscopic agglutination test (MAT). Six out of 50 animals had titres, all less than 100. Three of these animals had titres to serovar mini, 1 animal to tarrasovi, and 3 animals had multi-serovar reactions, 1 to mini and hardjo, and 1 to tarrasovi, copenhageni and pomona.
Asunto(s)
Animales Salvajes/inmunología , Leptospirosis/veterinaria , Pruebas de Aglutinación , Animales , Reservorios de Enfermedades , Leptospirosis/inmunología , Pruebas Serológicas , SudáfricaRESUMEN
An in situ thermogelling, mucoadhesive formulation based on N-trimethyl chitosan chloride has been evaluated for its potential to affect the transmucosal delivery of insulin via the nasal route. In vitro studies at a physiologically relevant temperature (ca. 35 °C) have shown that the formulation releases most of its insulin load (ca. 70%) in a non-Fickian manner during the timescale over which the sol-to-gel transition (ca. 8 min) takes place, and also that, once gelation is complete, the release of the remainder of the therapeutic content follows first order kinetics over at least sixty minutes. Investigations on the effects of the application of the same formulation to a modelled nasal mucosa (Calu-3 cell monolayer) have indicated the capability of the formulation to induce the transient opening of tight junctions. Cytotoxic investigations have shown that the formulation exhibits negligible detrimental effects to the integrity of these monolayers. The in vivo potential of the nasal formulation to act as a once-a-day dosage form for the intranasal delivery of insulin has been demonstrated in a diabetic-rat model.
RESUMEN
Towards the development of a thermosensitive drug-delivery vehicle for nasal delivery, a systematic series of N-trimethyl chitosan chloride polymers, synthesised from chitosans of three different average molecular weights, have been co-formulated into a hydrogel with poly(ethylene glycol) and glycerophosphate. Rheological evaluations have shown that hydrogels derived from N-trimethyl chitosan with a low degree of quaternisation and high or medium average molecular weight exhibit relatively short sol-gel transition times at physiologically relevant temperatures. Also, the same hydrogels display good water-holding capacity and strong mucoadhesive potential, and their mixtures with mucus exhibit rheological synergy. An aqueous hydrogel formulation, derived from N-trimethyl chitosan of medium average molecular weight and low degree of quaternisation, appears particularly promising in that it exhibits most favourable rheological and mucoadhesive behaviour and a sol-gel transition that occurs at 32.5°C within 7 min.